5850 Canoga Ave. Suite 400 Woodland Hills, CA, 91367
(+1) 800-988-3782
OTC Markets - BMCS

NewsNovember 8, 202136095BioTech Medics, Inc. Provides a Company Update as The Firm Anticipates Its Name Change To Become Approved

Taking seamless key performance indicators offline to maximise the long tail. Keeping your eye on the ball while performing a deep dive. Completely synergize resource taxing relationships via premier niche markets. Professionally cultivate one-to-one customer service with robust ideas.

WOODLAND HILLS, CA / ACCESSWIRE / November 8, 2021 / BioTech Medics, Inc. (OTC PINK:BMCS) announces that the Company continues to cooperate with FINRA to effectuate the Company’s name change from Bio Tech Medics to BMCS Sumcoin Index Fund Inc.

According to Anthony K. Miller, CEO, Management continues to reply to every regulatory inquiry with hopes this name change will be effective immediately. Over the past 2 months there has been minimal to no additional question regarding this corporate action, and Management is in contact daily with FINRA anticipating that this is the day when it will become the effective date. BMCS has been under an extensive micro review for over a couple months primarily because of the Digital Asset industry is under significant review by this regulatory agency. Once this name change is approved Management will begin a significant “project launch and awareness campaign” to provide the financial and investor community with our new business blueprint. Over 2 months ago, we finalized our new website that provides detailed information on this new direction, and that site will become live once the name change is effective. We have also built a knowledgeable team of professionals that understand digital markets and the intersection of this currency cross markets; now totalling 15 knowledgeable staff members. BMCS has a tremendous business model that is patterned after other companies in this Digital Asset space and Management has been actively accumulating significant Sumcoin from multiple sources that will be utilized to execute our business plan and to increase our NAV from what we last reported. We are excited about our potential earning power and last week management filed an application with OTC Markets to move BMCS to the OTCQB tier with the hope that we can move to OTCQX in 2022. Management appreciates the patience of its investors and hopeful that after we get to our project launched, the trajectory of our venture will be significantly positive and lucrative. Our goal is to make Sumcoin as liquid as other currencies in this our digital ecosystem; commented Miller”

READ MORE ABOUT SUMCOIN: https://www.sumcoin.org/

About BioTech Medics, Inc.: BioTech Medics, Inc is a publicly traded Wyoming company traded on the OTC Markets under the stock symbol BMCS located in Los Angeles California. BioTech Medics Inc. has historically been a biotech firm however, now a “Digital Asset Firm” focusing on Sumcoin (the world’s first indexed currency) one of the most significant currencies in the world.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the expected projects of BioTech Medics, Inc., and related companies. All statements that are included in this Press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements involve known and unknown risks, assumptions, uncertainties, and other factors. Statements made in the future tense, and statements using-words-such as “may, “can,” “could,” “should,” “predict,” “aim'” “potential,” “continue,” “opportunity,” “intend ” “goal,” “estimate,” “expect,” “expectations,” “project,” “projections,” “plans,” “anticipates,” “believe,” “think,” “confident” “scheduled” or similar expressions are intended to identify forward-looking statements. Forward-looking statements are not a guarantee of performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and are beyond our control.

These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this report and readers should carefully review this report in its entirety. We disclaim any obligation to update any of these forward-looking statements as a result of new information, future events, or otherwise, except as expressly required by law. Further information on our risk factors is contained in our filings with the OTC Markets and the SEC website. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

EMAIL: tony@biotecmedics.com
WEBSITE: www.biotecmedics.com
PHONE: 800.988.3782

SOURCE: BioTech Medics Inc